Advertisement

Topics

PubMed Journals Articles About "HLA-Compatible Related Or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated By The CliniMACS System In The Treatment Of Patients With Hematologic Malignancies" RSS

14:30 EDT 23rd March 2019 | BioPortfolio

HLA-Compatible Related Or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated By The CliniMACS System In The Treatment Of Patients With Hematologic Malignancies PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest HLA-Compatible Related Or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated By The CliniMACS System In The Treatment Of Patients With Hematologic Malignancies articles that have been published worldwide.

More Information about "HLA-Compatible Related Or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated By The CliniMACS System In The Treatment Of Patients With Hematologic Malignancies" on BioPortfolio

We have published hundreds of HLA-Compatible Related Or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated By The CliniMACS System In The Treatment Of Patients With Hematologic Malignancies news stories on BioPortfolio along with dozens of HLA-Compatible Related Or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated By The CliniMACS System In The Treatment Of Patients With Hematologic Malignancies Clinical Trials and PubMed Articles about HLA-Compatible Related Or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated By The CliniMACS System In The Treatment Of Patients With Hematologic Malignancies for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of HLA-Compatible Related Or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated By The CliniMACS System In The Treatment Of Patients With Hematologic Malignancies Companies in our database. You can also find out about relevant HLA-Compatible Related Or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated By The CliniMACS System In The Treatment Of Patients With Hematologic Malignancies Drugs and Medications on this site too.

Showing "Compatible Related Unrelated Donors With CD34 Enriched cell" PubMed Articles 1–25 of 44,000+

Factors predicting peripheral blood progenitor cell mobilization in healthy donors in the era of related alternative donors: Experience from a single center.

Poor mobilization results are unexpected after G-CSF-induced peripheral blood stem cell collection in healthy donors. However, 2%-5% of the donors are poor mobilizers. Factors predicting CD34+-cell yield after mobilization in related alternative donors are still poorly known.


Allogeneic stem cell transplantation from unrelated donors in acute leukaemia.

To summarize the past and current knowledge of the use of unrelated donors (URDs) in allogeneic stem cell transplantation for patients with acute leukaemia.

Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis.

Allogeneic hematopoietic cell transplantation is frequently used to treat malignant and non-malignant conditions, and many patients lack a human leukocyte antigen (HLA) matched related or unrelated donor. For those patients, available alternative graft sources include HLA mismatched unrelated donors, cord blood, or haplo-identical donors. These graft sources have unique characteristics and associated outcomes requiring graft-specific variations to conditioning regimens, graft-versus-host disease prophylaxis...


Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies.

Haploidentical transplantations have achieved comparable survival as HLA fully matched unrelated donors. When choosing the best donor for HLA-haploidentical transplantations, most institutions prioritize using young male donors over mother donors. In a retrospective study we compared outcomes in mother donor and unrelated donor transplantations. We found that both 2-year overall survival and 2-year leukemia-free survival were comparable between mother donor group and unrelated donor group (74.8% versus 72.9...

The Effect of Aging and Pre-Donation Comorbidities on the Related PBSC Donor Experience: A Report from the Related Donor Safety Study (RDSafe).

The development of reduced intensity approaches for allogeneic hematopoietic cell transplantation has resulted in growing numbers of older related donors (RD) of PBSC. The effects of age on donation efficacy, toxicity, and long-term recovery in RD are poorly understood. To address this we analyzed hematologic variables, pain, donation-related symptoms and recovery in 1211 related PBSC donors aged 18-79 enrolled in the Related Donor Safety Study (RDSafe). RD >60 had a lower median CD34+ level pre-apheresis c...

Nucleated red blood cells as a novel indicator of CD34 cell content in umbilical cord blood.

Umbilical cord blood (UCB) has become an important source of transplantable CD34 hematopoietic progenitor cells. Cord blood banks (CBBs) can increase their efficiency by minimizing the processing of UCB units with low CD34 content, which have a lower likelihood of transplant utilization. We sought to identify a readily available preprocessing metric that would correlate with CD34 cell counts, without the cost of additional analysis.

HLA mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis.

Recently, haplo-identical transplantation (haplo) using post-transplant cyclophosphamide (PTCy) has been reported to give very encouraging results in patients with hematological malignancies. Patients who have no HLA-matched donor currently have the choice between a mismatched unrelated donor, an unrelated cord blood donor and a haplo-identical related donor. The aim of our study is to compare the outcome of patients with myelodysplastic syndrome (MDS) who have been transplanted from a haplo-identical donor...

Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow allografts have improved Long-term Overall and Graft-versus-Host Disease, Relapse-Free Survival.

Peripheral Blood (PB) or Bone Marrow (BM) from unrelated donors can serve as a graft source for hematopoietic cell transplantation. Currently, PB is most commonly used in roughly 80% of adult recipients. Determining the long-term impact of graft source on outcomes would inform this decision.

KIR Donor Selection: Feasibility in Identifying Better Donors.

We previously reported that AML transplants using KIR B haplotype Better or Best (≥2 B activating gene loci ± Cen B/B) unrelated donors (URD) yield less relapse and better survival. In this prospective trial we evaluated 535 AML searches from 14 participating centers with centralized donor KIR genotyping for donor selection. This represented 3-48% of all AML searches (median 20%) per center totaling 3 to 172 patients (median 22) per center. Donor KIR genotype was reported at a median of 14 days after req...

Antibody-Armed Platelets for the Regenerative Targeting of Endogenous Stem Cells.

Stem cell therapies have shown promise in treating acute and chronic ischemic heart disease. However, current therapies are limited by the low retention and poor integration of injected cells in the injured tissue. Taking advantage of the natural infarct-homing ability of platelets, we engineered CD34 antibody-linked platelets (P-CD34) to capture circulating CD34-positive endogenous stem cells and direct them to the injured heart. In vitro, P-CD34 could bind to damaged aortas and capture endogenous stem cel...

A Method to Isolate CD34+ Mononuclear Cells from Canine Peripheral Blood.

Embryonic stem cells are pluripotent whereas adult stem cells are multipotent in nature. In recent years, evidence suggests that adult stem cells not only differentiate into specific cell lineages but also transdifferentiate into multiple cell lineages. Progenitor cells are found in adult bone marrow, blood, and other organs and differentiate into numerous cell lineages regardless of origin. Identifying a subset that can differentiate into mature endothelial cells is essential. This article describes periph...

Association between height and circulating CD34-positive cells taken into account for the influence of enhanced production among elderly Japanese men: a cross-sectional study.

Recent studies have revealed an inverse association between height and cardiovascular disease and that endothelial progenitor cells (CD34-positive cells) contribute to vascular maintenance, which is associated with cardiovascular disease. However, evidence of the association between height and CD34-positive positive cells among elderly participants is limited. To assess this association, we conducted a cross-sectional study of 231 elderly Japanese men aged 65-69. Since enhanced production of circulating CD3...

Bone Marrow versus Peripheral Blood from Unrelated Donors for Children and Adolescents with Acute Leukemia.

As graft versus host disease (GVHD) rates are higher after unrelated donor transplantation, we examined whether there would be differences in transplant outcomes by graft type in children and adolescents with acute leukemia. The primary endpoint was overall survival. We studied 872 patients aged less than 18 years transplanted with bone marrow (n = 650) or peripheral blood (n = 222) from unrelated donors. The characteristics of the two groups were comparable except recipients of bone marrow were you...

Characterization of inv(3) cell line OCI-AML-20 with stroma dependent CD34 expression.

Acute myeloid leukemia (AML) is a complex, heterogeneous disease with variable outcomes following curative intent chemotherapy. AML with inv(3) is a genetic subgroup characterized by a very low response rate to current induction type chemotherapy and hence has among the worst long term survivorship of the AMLs. Here, we describe OCI-AML-20, a new AML cell line with inv(3) and deletion of chromosome 7; the latter is a common co-occurrence in inv(3) AML. In OCI-AML-20, CD34 expression is maintained and requir...

CD3/CD19 depleted matched and mismatched unrelated donor hematopoietic stem cell transplant with targeted T cell addback is associated with excellent outcomes in pediatric patients with non-malignant hematologic disorders.

Unrelated donor (URD) hematopoietic stem cell transplantation (HSCT) is increasingly being utilized to cure non-malignant hematologic diseases (NMHD) in patients who lack HLA matched related donors (MRD). Both graft rejection and graft vs host disease (GVHD) remain major barriers to safe and effective transplant for these patients requiring URDs. Partial T cell depletion combined with peripheral stem cell transplantation (pTCD-PSCT), has the potential advantages of providing a high stem cell dose to facilit...

Analysis of hematopoietic stem cells using a composite approach.

Stem cells or Cancer stem cells (CSCs) have now been identified in different type of tissues by using surface markers. Functional assays such as ALDEFLUOR and side population which are marker independent have been additional approaches. However, whether all these approaches identify the same population of cells remain uncertain. To address this issue we have used hematopoietic stem cells as a model. Peripheral blood stem cells enumerated by CD34 are used routinely in bone marrow transplantation which suppor...

Expression of CD25 fluctuates in the leukemia-initiating cell population of CD25-positive AML.

CD25 is expressed on leukemic cells in 10-20% cases of acute myeloid leukemia (AML), and its expression is associated with poor prognosis. We reevaluated the relationship between CD25 expression and the leukemia-initiating cell (LIC) properties of AML using a patient-derived xenograft model. We divided lineage marker-negative (Lin-) CD34+CD38- or Lin-CD34+ cells from CD25-positive AML into CD25-positive and -negative populations, and then transplanted each population into NOD.Cg-PrkdcscidIl2rgtm1Wjl/Sz mice...

Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III).

Little information exists on red blood cell (RBC) alloimmunization in healthy US blood donors, despite the potential significance for donors themselves, blood recipients, and the blood center.

Pro-inflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes.

Graft versus host disease (GVHD) is a frequent cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (allo-HCT). GVHD occurs when donor lymphocytes are activated by inflammatory cytokines and alloantigens. The role of donor biological characteristics, such as basal inflammation, has not been investigated as a risk factor for GVHD, but is theoretically transferrable to the recipient. We evaluated donor serum and plasma concentrations of cytokines and adipokines (IL-1β, IL-...

Barriers to Allogeneic Hematopoietic Stem Cell Transplant for Human T-Cell Lymphotropic Virus 1 associated Adult T-Cell Lymphoma-Leukemia in the United States: Experience from a large cohort in a major tertiary center.

In the United States (U.S.), Adult T-Cell Lymphoma-Leukemia (ATLL) carries a dismal prognosis and mainly affects immigrants from Human T-Cell Lymphotropic Virus 1 (HTLV-1) endemic areas. Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) can be effective and is recommended as an upfront treatment in the NCCN guidelines. We studied the barriers to alloHSCT in one of the largest ATLL populations in the U.S. Comprehensive chart and donor registry reviews were conducted for 88 ATLL patients treated at Mon...

A dual strategy to optimize hematopoietic progenitor cell collections: validation of a simple prediction algorithm and use of collect flow rates guided by mononuclear cell count.

Previous prediction algorithms to achieve target CD34+ goals have not been widely adopted, with many centers still using a set volume to process for hematopoietic progenitor cell collections. This may be because previous algorithms are challenging to implement. Additionally, no study has yet examined the utility of adjusting the collect flow rate (CFR) based on the donor's preprocedure total mononuclear cell (MNC) count, which correlates with CD34+ yield.

The role of regulatory T cells in non-inherited maternal antigen-related tolerance in cord blood: an in vitro study.

Cord blood (CB) is an alternative stem cell source for allogeneic haematopoietic stem cell transplantation (HSCT). The unique advantages with CB as a stem cell source lies in a degree of permissibility for human leukocyte antigen (HLA) mismatch, rapid availability, and relatively risk-free cell collection. Since HLA is highly polymorphic and population specific, optimal HLA matched unrelated donors or cord blood units (CBUs) may not be available. In view of the chance that matched CBUs which include non-inh...

MiR-9 Controls Chemotactic Activity of Cord Blood CD34⁺ Cells by Repressing CXCR4 Expression.

Improved approaches for promoting umbilical cord blood (CB) hematopoietic stem cell (HSC) homing are clinically important to enhance engraftment of CB-HSCs. Clinical transplantation of CB-HSCs is used to treat a wide range of disorders. However, an improved understanding of HSC chemotaxis is needed for facilitation of the engraftment process. We found that ectopic overexpression of miR-9 and antisense-miR-9 respectively down- and up-regulated C-X-C chemokine receptor type 4 (CXCR4) expression in CB-CD34⁺ ...

Intraoperative Management of a Patient With Impaired Cardiac Function Undergoing Simultaneous ABO-Compatible Liver and ABO-Incompatible Kidney Transplant From 2 Living Donors: A Case Report.

Combined liver and kidney transplant is a very complex surgery. To date, there has been no report on the intraoperative management of patients with impaired cardiac function undergoing simultaneous ABO-compatible liver and ABO-incompatible kidney transplant from 2 living donors.

Comparison of outcomes of allogeneic transplantation for primary myelofibrosis among hematopoietic stem cell source groups.

The choice of alternative donor is a major issue in allogeneic hematopoietic stem cell transplantation for patients with primary myelofibrosis (PMF) who have no HLA-matched related donor. A retrospective study was conducted using the national registry data of 224 PMF patients to compare the outcomes of first allogeneic transplantation from HLA-matched related donor bone marrow (Rtd-BM), HLA-matched related donor peripheral blood stem cells (Rtd-PB), HLA-matched unrelated donor bone marrow (UR-BM), unrelated...


Advertisement
Quick Search
Advertisement
Advertisement